🇺🇸 FDA
Patent

US 10363247

(S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer

granted A61KA61K31/4439A61P

Quick answer

US patent 10363247 ((S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer) held by Karyopharm Therapeutics Inc. expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Karyopharm Therapeutics Inc.
Grant date
Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/4439, A61P, A61P17/02, A61P17/06